WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000024391) CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/024391    International Application No.:    PCT/US1999/025221
Publication Date: 04.05.2000 International Filing Date: 27.10.1999
Chapter 2 Demand Filed:    26.05.2000    
IPC:
A61K 31/00 (2006.01), A61K 31/02 (2006.01), A61K 31/122 (2006.01), A61K 31/365 (2006.01), A61K 31/407 (2006.01), A61K 31/55 (2006.01)
Applicants: YALE UNIVERSITY [US/US]; 451 College Street New Haven, CT 06520-8336 (US)
Inventors: CAPLAN, Michael, J.; (US).
EGAN, Marie, E.; (US)
Agent: JARRELL HERSCHBACH, Brenda; Choate, Hall & Stewart Exchange Place 53 State Street Boston, MA 02109 (US)
Priority Data:
60/105,806 27.10.1998 US
Title (EN) CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY
(FR) CONDUCTANCE DE PROTEINES MAL REPLIEES DANS LA VOIE SECRETOIRE
Abstract: front page image
(EN)This invention provides the methodology and agents for treating disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention of proteins. Thus, the methods and agents of the present invention provide for the release of normally retained proteins from the endoplasmic reticulum. The present invention is particularly useful for treating any disease or clinical condition which is at least partly the result of endoplasmic reticulum-associated retention or degradation of mis-assembled or mis-folded proteins. In particular, thapsigargin, cyclopiazonic acid, DBHQ or halothane can be used to allow the release of $g(D)F508CFTR or of a secretion-incompetent variant null (Hong Kong) of $g(a)¿1?-antitrypsin, in order to treat cystic fibrosis or chronic obstructive pulmonary disease (pulmonary emphysema) respectively.
(FR)L'invention concerne une méthodologie et des agents permettant de traiter les maladies ou états cliniques dus, en partie au moins, à la rétention de protéines associée au réticulum endoplasmique. Ainsi, les techniques et les agents de la présente invention permettent la libération par le réticulum endoplasmique des protéines qu'il retient normalement. La présente invention est particulièrement utile pour traiter les maladies ou états cliniques résultant, en partie au moins, de la rétention ou de la dégradation associée au réticulum endoplasmique de protéines mal assemblées ou mal repliées.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)